Gene-Editing shot aims to slash cholesterol that drugs Can't touch

NCT ID NCT06451770

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This early-stage study tests a single dose of VERVE-201, a gene-editing therapy, in 36 adults with dangerously high cholesterol and triglycerides that don't respond to standard treatments. The treatment aims to permanently turn off a liver gene (ANGPTL3) to lower blood fats. The main goal is to check safety, but researchers will also measure how well it works.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERCHOLESTEROLEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hypercholesterolemia hyperlipidemia Hyperlipoproteinemia Type II hypertriglyceridemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Clinical Study Center

    RECRUITING

    Clearwater, Florida, 33756, United States

  • Clinical Study Center

    RECRUITING

    Miami Lakes, Florida, 33016, United States

  • Clinical Study Center

    RECRUITING

    Port Orange, Florida, 32127, United States

  • Clinical Study Center

    RECRUITING

    New York, New York, 10029, United States

  • Clinical Study Center

    RECRUITING

    Adelaide, Australia

  • Clinical Study Center

    RECRUITING

    Melbourne, Australia

  • Clinical Study Center

    RECRUITING

    Chicoutimi, Canada

  • Clinical Study Center

    RECRUITING

    Montreal, Canada

  • Clinical Study Center

    RECRUITING

    Toronto, Canada

  • Clinical Study Center

    RECRUITING

    Amsterdam, Netherlands

  • Clinical Study Center

    RECRUITING

    Cape Town, South Africa

  • Clinical Study Center

    RECRUITING

    Johannesburg, South Africa

  • Clinical Study Center

    RECRUITING

    Liverpool, United Kingdom

  • Clinical Study Center

    RECRUITING

    London, United Kingdom

  • Clinical Study Center

    RECRUITING

    Manchester, United Kingdom

  • Clinical Study Center 2

    RECRUITING

    Manchester, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.